Market Access EAPs: Market access outside of the US and Western Europe In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals about early access programmes.
Market Access NICE and the controversy over a ‘clinically distinct disease... Payers worldwide are struggling with a new generation of precision medicines that come with a hefty price tag.
Market Access Transformative trends with real-world data from early access... The complex and changing needs of patients with life-threatening conditions has led many health authorities to introduce early access programmes.
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.